Related references
Note: Only part of the references are listed.P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer
Tore B. Stage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
Marta Bellesini et al.
CLINICAL DRUG INVESTIGATION (2020)
Species differences in the drug-drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs
Keiko Minami et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir
Wendy Ankrom et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling
Size Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
Polina German et al.
CLINICAL PHARMACOKINETICS (2018)
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
Lai Wei et al.
HEPATOLOGY INTERNATIONAL (2018)
Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection
Ossama A. Ahmed et al.
INFECTION AND DRUG RESISTANCE (2018)
Hepatitis C in Egypt - past, present, and future
Ahmed Elgharably et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C
Polina German et al.
CLINICAL PHARMACOKINETICS (2016)
Regression of coronary atherosclerosis: Current evidence and future perspectives
Konstantinos C. Koskinas et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2016)
Genotype specific peripheral lipid profile changes with hepatitis C therapy
Mark R. Pedersen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Pleiotropic effects of statins in the diseases of the liver
Martin Janicko et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
Shyam Patel et al.
CASE REPORTS IN MEDICINE (2016)
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
Brian J. Kirby et al.
CLINICAL PHARMACOKINETICS (2015)
Sofosbuvir for treatment of chronic hepatitis C
Sarah Kattakuzhy et al.
HEPATOLOGY INTERNATIONAL (2015)
Changing the face of hepatitis C management - the design and development of sofosbuvir
Bennett C. Noell et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects
Jill Denning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase
A. A. El-Sisi et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2013)
Hepatitis C virus diversity and hepatic steatosis
P. Roingeard
JOURNAL OF VIRAL HEPATITIS (2013)
Hepatitis C virus: virology and life cycle
Chang Wook Kim et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2013)
Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans
Louise M. Henderson et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans
Takao Watanabe et al.
DRUG METABOLISM AND DISPOSITION (2010)
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents
Carolyn A. Goard et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial
Jacqueline G. O'Leary et al.
HEPATOLOGY (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Different anti-HCV profiles of statins and their potential for combination therapy with interferon
Masanori Ikeda et al.
HEPATOLOGY (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2006)
Clinical pharmacokinetics of atorvastatin
H Lennernas
CLINICAL PHARMACOKINETICS (2003)
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
EJ Wang et al.
PHARMACEUTICAL RESEARCH (2001)
HMG-CoA reductase inhibitors and P-glycoprotein modulation
K Bogman et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Share Paper
